Dyne Therapeutics prices $300M public offering of 17.15M shares at $17.50/share

Dyne Therapeutics, Inc.

Gross proceeds ~$300.1M from 17,150,000 shares; net proceeds ~$281.6M after discounts and expenses.
Underwriters have 30-day option for up to 2,572,500 additional shares; if exercised, net ~$323.9M.
Proceeds plus existing cash expected to fund operations through 2025.
Offering led by Morgan Stanley, J.P. Morgan, Jefferies, Stifel; expected to close January 9, 2024.
Shares sold by Dyne; no selling stockholders participating.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.